Denali Therapeutics registers Phase 1/1b trial of DNL921 in Alzheimer's diseaseAug 11Trial updateDenali Therapeutics Inc.DNL921
Denali reports first full AVLAYAH quarter, advances Alzheimer's pipeline, sells PRV for $195 millionAug 6Quarterly updateDenali Therapeutics Inc.tividenofusp alfa-eknm
Sign inSign in